Health Care · Pharmaceutical Preparations

MNPR Monopar Therapeutics SEC Filings & Insider Trading Activity 2026

company
CIK 164546991 filings
Russell 2000

MNPR at a glance

Monopar Therapeutics (MNPR, SEC CIK 1645469) filed its latest 10-K annual report on March 27, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Monopar Therapeutics (MNPR) reported revenue of $0 and a net loss of $13.7 million. Diluted EPS was -$1.85.
  • As of September 30, 2026, 20 institutional investment managers tracked by SignalX reported holding Monopar Therapeutics (MNPR) shares worth $101.7 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Tsuchimoto Kim R on November 4, 2026 of 1,295 shares at $70.75 per share.
  • In the last 90 days, MNPR insiders reported 0 open-market purchases ($0) and 34 open-market sales ($5.3M) on Form 4, a net sale of $5.3M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$0
10-K XBRL
Insiders · 90 days
0 buys · 34 sells
Net −$5.3M
13F holders
20 funds
$101.7M · −2 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New regulatory risk: rolling ALXN1840 NDA submission and review, with potential U.S. government shutdown delays
  • Most material program change: Alexion terminated ALXN1840 Wilson disease development after Phase 2 review and regulator discussions
  • Operational risk: radiopharmaceutical programs depend on adequate radioisotope supply and time-limited product shelf life
  • Market risk: larger competitors possess greater capital, organizational, marketing and sales resources
  • Financial risk: $104.9 million accumulated deficit, with operations funded through March 31, 2028 by current cash and investments

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no approved drugs or product sales
  • Net loss $6.2M vs $3.4M YoY, operating loss $7.5M vs $4.1M
  • R&D expense $4.4M vs $2.6M YoY, G&A expense $3.0M vs $1.5M
  • Cash, equivalents and investments $129.4M as of September 30, 2026
  • Operating cash outflow $12.9M vs $9.1M YoY, funds expected through March 31, 2028; NDA rolling submission completion anticipated within several weeks

AI summary of the MNPR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results for quarter ended September 30, 2026
  • Press release furnished as Exhibit 99.1, containing the company’s reported results and management commentary

Item EX-99.1: Item EX-99.1

  • Q3 2026 net loss widened to $6.2M, or $0.72 per share, from $3.4M, or $0.48 per share
  • Cash, equivalents and investments totaled $129.4M, supporting operations through at least March 31, 2028
Filed Aug 12, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 2026 net loss widened to $5.3M, or $0.62 per share, from $2.5M, or $0.35 per share
  • Cash, equivalents and investments totaled $134.3M, supporting operations through at least December 31, 2027

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results for quarter ended June 30, 2026 announced by Monopar Therapeutics
  • Full financial details and management commentary contained in Exhibit 99.1 press release
Filed Jul 22, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Rolling FDA NDA submission initiated for ALXN1840 (tiomolibdate choline) in Wilson disease
  • Regulatory milestone potentially accelerates FDA review of Monopar’s lead therapeutic candidate

Item EX-99.1: Item EX-99.1

  • Rolling NDA submission initiated for ALXN1840, advancing Monopar’s lead program toward potential U.S. approval in Wilson disease
  • FDA filing authorization enables completed sections to undergo review before the application is complete

AI summaries of MNPR 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for MNPR

Don't miss the next MNPR filing

  • Alerts as it files. A push when MNPR files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut MNPR, by share count.
  • Ask anything. An AI agent that reads every MNPR filing and answers with sources.

MNPR alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Tsuchimoto Kim RMNov 4, 2026-
Tsuchimoto Kim RMNov 4, 2026$14.00
Tsuchimoto Kim RSellNov 4, 2026$70.75
Tsuchimoto Kim RSellNov 4, 2026$72.21
Tsuchimoto Kim RMNov 4, 2026-
Tsuchimoto Kim RSellNov 4, 2026$71.35
Tsuchimoto Kim RMNov 4, 2026$30.00
Anderson RaymondMNov 2, 2026$30.00

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$0$0$0
Operating Income-$8.8M-$16.2M-$16.7M
Net Income--$15.6M-$13.7M
Balance Sheet
Total Assets$7.3M$60.3M$140.7M
Equity$5.6M$55.0M$137.8M
ROE--28.3%-10.0%
Per Share
EPS$-0.61$-4.11$-1.85
Cash Flow
Operating CF-$7.9M-$6.4M-$12.2M

Source: XBRL data in Monopar Therapeutics (MNPR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate MNPR share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
MNPR shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202620$101.7M
Q2 202622$91.4M
Q1 202619$59.0M
Q4 202518$59.9M
Q3 202513$46.2M
Q2 202514$14.7M
Q1 20259$5.9M
Q4 20242$1.2M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 117 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

MNPR filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 12, 2026Analysis-
10-QNov 12, 2026Analysis
4Nov 4, 2026--
4Nov 4, 2026--
4Oct 20, 2026--
4Oct 5, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Sep 28, 2026--
4Aug 28, 2026--
4Aug 28, 2026--
4Aug 27, 2026--
4Aug 27, 2026--
4Aug 27, 2026--
10-QAug 12, 2026Analysis
8-KAug 12, 2026Analysis-
8-KJul 22, 2026Analysis-
4Jul 2, 2026--
4Jul 2, 2026--
4Jul 2, 2026--
4Jun 30, 2026--
8-KJun 30, 2026Analysis-
8-KJun 26, 2026Analysis-
8-KJun 23, 2026Analysis-

Related Health Care companies

All Health Care →

MNPR SEC filings: frequently asked questions

Are MNPR insiders buying or selling?

In the last 90 days, Monopar Therapeutics (MNPR) officers, directors and 10% owners reported no open-market purchases and 34 open-market sales worth $5.3 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold MNPR stock?

As of September 30, 2026, the largest Monopar Therapeutics (MNPR) holders among the 13F filers tracked by SignalX were BlackRock ($27.8 million), State Street Corp ($18.3 million), Vanguard Capital Management LLC ($17.4 million), Goldman Sachs Group ($7.0 million), BNY Mellon ($6.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was MNPR's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Monopar Therapeutics (MNPR) reported revenue of $0 and a net loss of $13.7 million. Diluted EPS was -$1.85. The figures come from the XBRL data in the 10-K.

What did MNPR report in its latest 8-K?

Monopar Therapeutics (MNPR) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for quarter ended September 30, 2026.

What are the latest MNPR SEC filings?

Monopar Therapeutics (MNPR) filed its latest 10-K annual report on March 27, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 4, 2026.

What is MNPR's SEC CIK number?

Monopar Therapeutics (MNPR)'s SEC Central Index Key (CIK) is 1645469. EDGAR lists every MNPR filing under that number.

Ask anything about MNPR

The research agent reads MNPR's filings, financials, insider trades and 13F holders, then answers with sources.